Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 27.36 USD 0.66% Market Closed
Market Cap: 2B USD

Wall Street
Price Targets

KNSA Price Targets Summary
Kiniksa Pharmaceuticals Ltd

Wall Street analysts forecast KNSA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KNSA is 37.3 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.

Lowest
Price Target
30.3 USD
11% Upside
Average
Price Target
37.3 USD
36% Upside
Highest
Price Target
47.25 USD
73% Upside
Kiniksa Pharmaceuticals Ltd Competitors:
Price Targets
PAR
Paradigm Biopharmaceuticals Ltd
155% Upside
301207
Hualan Biological Bacterin Inc
17% Upside
ASND
Ascendis Pharma A/S
39% Upside
AMGN
Amgen Inc
11% Upside
OCX
OncoCyte Corp
38% Upside
688278
Xiamen Amoytop Biotech Co Ltd
30% Upside
LEGN
Legend Biotech Corp
171% Upside
002007
Hualan Biological Engineering Inc
21% Upside

Revenue
Forecast

Revenue Estimate
Kiniksa Pharmaceuticals Ltd

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 3 years is 26%.

N/A
Past Growth
26%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KNSA's stock price target?
Price Target
37.3 USD

According to Wall Street analysts, the average 1-year price target for KNSA is 37.3 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.

What is Kiniksa Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
26%

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 3 years is 26%.

Back to Top